Q-omics provides the consensus-scored CSPG4P5 profile across patient tissues and cancer cell-line models. CSPG4P5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CSPG4P5 is differentially expressed in 4, with the highest sampling consensus in PAAD. Additionally, CSPG4P5 RNA expression shows 4,964 significant pathway-activity associations, with the highest sampling consensus in SKCM. Together, these results highlight COAD, PAAD, and SKCM as cancer lineages where CSPG4P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSPG4P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSPG4P5 survival associations across molecular data types. CSPG4P5 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSPG4P5 RNA expression–survival associations across cancer types. High CSPG4P5 expression shows unfavorable associations in COAD, KIRC, READ, CESC, LIHC and THYM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CSPG4P5 RNA expression.
This table summarizes CSPG4P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CSPG4P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSPG4P5 shows lower tumor expression in PAAD and PRAD and higher tumor expression in BRCA and KICH. The PAAD box plot shows higher CSPG4P5 RNA expression in normal versus tumor tissue (log2 FC = −0.025, t-test p = .037).
This table shows molecular features associated with CSPG4P5 in patient tissues and cancer cell lines. In patient samples, CSPG4P5 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
